FDA OKs Novartis' radiotherapy Lutathera for certain neuroendocrine tumors

Jan. 26, 2018 12:36 PM ETNovartis AG (NVS)By: Douglas W. House, SA News Editor
  • The FDA approves Novartis (NYSE:NVS +0.1%) unit Advanced Accelerator Applications S.A.'s LUTATHERA (lutetium Lu 177) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adult patients, an Orphan Drug indication.
  • LUTATHERA, a targeted therapy that carries a radioactive component, is the first drug of its kind approved in the U.S.
  • In general, neuroendocrine tumors, the second-most prevalent type of GI cancer, produce peptides that lead to symptoms. LUTATHERA targets the peptide receptor using octreotide, an analog of the peptide hormone somatostatin, linked to the radiopharmaceutical Lutetium-177.
  • Novartis completed its $3.9B acquisition of Advanced Accelerator on January 22.
  • Previously: Novartis scoops up Advanced Accelerator (Oct. 30, 2017)

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.